[144] Astera Labs, Inc. SEC Filing

Rhea-AI Filing Summary

Astera Labs, Inc. (ALAB) submitted a Form 144 notice reporting a proposed sale of 22,500 shares of common stock through UBS Financial Services Inc. on the NASDAQ with an aggregate market value of $4,014,398.25. The filing lists the securities to be sold on 08/27/2025.

The filing shows all 22,500 shares were acquired by the seller through RSU vesting on four dates: 11/15/2024 (2,187), 02/15/2025 (3,438), 05/15/2025 (8,437), and 08/15/2025 (8,438), which together equal the 22,500 shares proposed for sale. The filer reports nothing to report for securities sold in the past three months. The form includes the required signature attestation about absence of undisclosed material adverse information.

Positive

• Full disclosure of proposed sale size: 22,500 shares reported with aggregate market value of $4,014,398.25
• Clear acquisition history: all shares were acquired via RSU vesting on four specified dates totaling 22,500 shares
• Broker and exchange listed: UBS Financial Services Inc. on NASDAQ—provides execution details for market transparency
• No sales in prior three months: filer reports "Nothing to Report" for securities sold during the past 3 months

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice: insider proposes to sell 22,500 RSU-derived shares via UBS on NASDAQ; no recent sales reported.

The filing represents a standard Form 144 disclosure for a proposed sale under Rule 144. The transaction size is 22,500 shares with an aggregate market value reported at $4,014,398.25. All shares were acquired via RSU vesting on four stated dates, and the filer reports no securities sold in the prior three months. From a market-impact perspective, the filing itself gives no indication of material change to operating or financial performance; it is a disclosure of an intended sale subject to Rule 144 conditions and market execution via the listed broker.

Corporate Governance Expert

TL;DR: Compliance-focused filing: the seller attests to no undisclosed material adverse information and documents RSU-originated holdings being placed for sale.

The document fulfills regulatory transparency requirements for insider or affiliated-party dispositions. It details acquisition origin as RSU vesting and provides broker and exchange information, which supports proper market routing and recordkeeping. The filing's attestation about lack of undisclosed material information is the standard legal representation; no governance-related exceptions or caveats are presented in the content provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Avenue 4th Floor New York NY 10010	22500	4014398.25	166219140	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/15/2025	RSU Vest	Issuer			3438	02/15/2025	N/A
Common	11/15/2024	RSU Vest	Issuer			2187	11/15/2024	N/A
Common	05/15/2025	RSU Vest	Issuer			8437	05/15/2025	N/A
Common	08/15/2025	RSU Vest	Issuer			8438	08/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Astera Labs' (ALAB) Form 144 report?

The filing reports a proposed sale of 22,500 common shares through UBS Financial Services Inc. on the NASDAQ with an aggregate market value of $4,014,398.25.

When is the proposed sale of ALAB shares scheduled?

The Form 144 lists the approximate date of sale as 08/27/2025.

How were the 22,500 ALAB shares acquired?

All shares were acquired via RSU vesting on four dates: 11/15/2024 (2,187), 02/15/2025 (3,438), 05/15/2025 (8,437), and 08/15/2025 (8,438).

Did the filer sell any ALAB securities in the past three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months.

Who is the listed broker for the proposed ALAB share sale?

The broker is listed as UBS Financial Services Inc., 11 Madison Avenue, 4th Floor, New York, NY 10010.